Avacincaptad Pegol + Avastin + Lucentis + Eylea
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neovascular Age-Related Macular Degeneration
Conditions
Neovascular Age-Related Macular Degeneration
Trial Timeline
Oct 20, 2016 → Apr 24, 2018
NCT ID
NCT05571267About Avacincaptad Pegol + Avastin + Lucentis + Eylea
Avacincaptad Pegol + Avastin + Lucentis + Eylea is a phase 2 stage product being developed by Astellas Pharma for Neovascular Age-Related Macular Degeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT05571267. Target conditions include Neovascular Age-Related Macular Degeneration.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05571267 | Phase 2 | Terminated |
Competing Products
20 competing products in Neovascular Age-Related Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Avacincaptad Pegol | Astellas Pharma | Phase 1 | 33 |
| Avacincaptad Pegol + Lucentis | Astellas Pharma | Phase 2 | 52 |
| KHK4951 + Aflibercept Injection | Kyowa Kirin | Phase 2 | 52 |
| Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab Control | AbbVie | Phase 3 | 77 |
| Ranibizumab + Local Steroid + Topical Steroid | AbbVie | Phase 2 | 52 |
| Lucentis | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab | Novartis | Pre-clinical | 23 |
| ranibizumab | Novartis | Approved | 85 |
| brolucizumab + ranibizumab + aflibercept | Novartis | Pre-clinical | 23 |
| Beovu | Novartis | Pre-clinical | 23 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| Intraviteal Ranibizumab 0.5mg | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |